Trials / Completed
CompletedNCT00334828
ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,000 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare eritoran tetrasodium and placebo in patients with severe sepsis and to demonstrate a reduction of mortality from all causes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eritoran tetrasodium | Intravenous infusion at a total dose of 105 mg. |
| DRUG | Placebo | Matching placebo; intravenous infusion. |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2011-01-01
- First posted
- 2006-06-08
- Last updated
- 2017-07-25
Locations
251 sites across 24 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Hong Kong, Israel, Italy, Japan, Netherlands, Poland, Portugal, South Africa, South Korea, Spain, Switzerland, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT00334828. Inclusion in this directory is not an endorsement.